To update previously reported outcomes of modified-template post-chemotherapy retroperitoneal lymph node dissection (PC-RPLND) in appropriately selected patients with metastatic non-seminomatous germ cell tumour (NSGCT), as our previous report was criticised for short follow-up and so we now provide a long-term update on this cohort.
Introduction
Surgical resection of retroperitoneal disease in patients with testicular cancer has evolved remarkably over the last 50 years. Treatment options for patients with stage II nonseminomatous germ cell tumour (NSGCT) include primary retroperitoneal lymph node dissection (RPLND) in early stage disease or three to four courses of induction chemotherapy followed by surgery if the tumour persists in the retroperitoneum for more advanced stages. With a better understanding of the distribution of lymph node metastases [1] [2] [3] , modification of dissection templates has led to decreased morbidity. In select series over the past 30 years, several centres have shown improved rates of preservation of antegrade ejaculation in the modified unilateral templates during primary RPLND without compromise of oncological outcomes [4] [5] [6] . Concurrently, there has been a declining acute morbidity of chemotherapy. We recognised these developments and questioned whether a full-bilateral template is appropriate in all patients with postchemotherapy residual retroperitoneal masses.
We previously reported on a cohort of 100 patients who underwent modified-template post-chemotherapy RPLND (PC-RPLND) for NSGCT between 1991 and 2004 [7] . We demonstrated therapeutic efficacy, with only four patients developing recurrent disease outside of the retroperitoneum. The recurrence-free survival (RFS) rate was 95% at 2 and 5 years. However, with a median follow-up of 32 months, the study was criticised because it was felt that follow-up was too brief. Therefore, the objective of the present study was to evaluate the long-term oncological outcomes of this same group of patients presented in the original paper.
Patients and Methods
After Institutional Review Board approval, our prospectively maintained testicular cancer database was queried for all patients who underwent modified PC-RPLND between 1991 and 2004 and were part of our original study [7] . All patients who presented with metastatic, NSGCT with normal serum tumour markers and residual retroperitoneal disease on CT after initial cisplatin-based chemotherapy were reviewed. Only patients with tumour limited to the primary landing zone of the affected testis, both before and after chemotherapy, were included. Patients with late recurrent disease (disease recurrence >2 years after the last treatment), 'desperation' surgery (rising serum tumour markers during or after chemotherapy), or redo-resection were excluded.
The boundaries of our modified-template PC-RPLND were previously described [7] . In summary, a right-modified PC-RPLND included removal of the right common iliac (medial to the ureter), paracaval, precaval, retrocaval, and interaortocaval (IAC) lymph nodes. A left-modified PC-RPLND included removal of the preaortic, para-aortic, and left common iliac lymph nodes, while the additional removal of IAC lymph nodes superior to the inferior mesenteric artery was considered as 'full left modified'. The decision to perform a left-modified or a full-left-modified dissection was surgeon preference. The anatomical nodal region pathological findings were reported individually for each patient.
To assess long-term results, a search was performed to obtain current contact information for the previously identified patients. Patients were interviewed by telephone about recurrence and ejaculatory status. Additionally, referring physicians were contacted for the most recent clinical information. Follow-up was defined as the time interval between PC-RPLND and the date of last imaging or clinical visit or of date of recurrence. Therapeutic or oncological efficacy was evaluated by determining recurrence rates and overall survival rates using the Kaplan-Meier method. All statistical analysis was carried out using STATA v12.1 IC software.
Results
The study cohort included all 100 patients described previously [7] . In summary, 98 patients had good-risk disease, as defined by the International Germ Cell Consensus Group [8] , and received induction chemotherapy only, while two patients with poor-risk disease received second-line chemotherapy before surgery secondary for persistent marker elevation. All patients had normal serum tumour markers at the time of PC-RPLND. In all, 43 patients underwent a rightmodified dissection, 18 patients underwent a full-left-modified dissection, and 39 patients underwent a left-modified template. Most of our patients (94%) had clinical stage IIA disease (lymph node <2 cm) or IIB disease (lymph node <5 cm) preoperatively. Six patients had clinical stage IIC disease (lymph node >5 cm) preoperatively. Pathology revealed viable germ cell cancer in 2% of patients, teratoma in 62% of patients, and fibrosis in 36% of patients ( Table 1 ).
The median follow-up for all 100 patients was 10 years. Overall survival of the entire cohort at 10 years was 99% (Fig. 1) , and the RFS rate at 5 and 10 years was 93% and 92%, respectively (Fig. 2) . In all, seven patients developed recurrent disease at a median (range) of 11 (6-102) months (Table 2 ). Of these, three patients underwent full-leftmodified dissection, while one patient underwent leftmodified dissection and all had teratoma in the para-aortic lymph node package. All four of these patients also had recurrence in the chest or retrocrural space. The remaining three patients underwent a right-modified dissection, all with teratoma in the IAC lymph nodes at the time of PC-RPLND. One patient developed recurrent disease at 8 months over the right common iliac artery, lateral to the right ureter. Another developed recurrent disease at 6 months with tumour in the retrocrural space and right para-psoas region, lateral to the ureter. This was managed surgically and pathology revealed teratoma and yolk sac tumour. Adjuvant chemotherapy for this patient was not administered and there continues to be no evidence of disease 12 years after his PC-RPLND. The last patient developed recurrent disease at 11 months and had teratoma identified in the right inguinal canal. One patient developed recurrent disease in the right cervical region 33 months after PC-RPLND, and underwent salvage chemotherapy followed by a cervical lymph node resection. Unfortunately, he developed recurrent tumours in the chest and eventually succumbed to the disease at 55 months.
The postoperative complications were previously reported on this cohort of patients [7] , and there were no new short-or long-term complications with this update. Reproductive status was able to be obtained for 44 patients (Table 3) . Most of these patients (43 patients, 97.7%) reported normal antegrade ejaculation. Of these, 17 patients (39.5%) went on to have a post-RPLND pregnancy.
Discussion
Previously, a full-bilateral RPLND has been standard for residual tumour. However, there has been a progressive increase in the proportion of patients who present with lowstage disease [9, 10] . Furthermore, there has been an increase in systemic platinum-based chemotherapy use in low-volume retroperitoneal disease and with tumours restricted to the primary landing zone of the affected testis [10] . As the number of testicular cancer survivors increases, treatment-associated morbidity has become a crucial issue. The suitability of a fullbilateral dissection for all residual disease in all patients in all settings becomes a point of contention, as it is becoming clear that tailoring the therapy to the disease lowers morbidity.
We hypothesised that a modified PC-RPLND would have equal oncological efficacy in managing the retroperitoneum of a select group of patients without an increase in local recurrence or reduction in therapeutic outcome. By selecting patients for this modified template, who have unilateral disease burden both before and after chemotherapy, we assumed there would be no patients with contralateral microscopic disease. In our initial study, we identified four recurrences, all of which were outside the boundaries of a full-bilateral dissection template. The median follow-up was 32 months and the study was criticised for the lack of longterm analysis [11] . After extensive review, three additional recurrences outside the template were found for a total of These results confirmed our initial findings of all recurrences occurring outside the boundaries of a bilateral dissection. The most common site of recurrence was in the chest and three were subdiaphragmatic. The iliac artery recurrence, parapsoas recurrence, as well as the inguinal canal recurrence were all lateral to the ureter and, therefore, were outside the boundaries of a full-bilateral template. All but one recurrence were salvaged with resection alone.
Several studies evaluating modified-template outcomes are among patients in a wide variety of clinical settings [12, 13] . In a recent series, Carver et al. [13] reported a 7-32% incidence of extra-template retroperitoneal disease, depending on the modified template used [3, [14] [15] [16] . That series had a wide inclusion criteria for patients eligible for PC-RPLND and included patients with elevated serum tumour markers, as well as retroperitoneal disease of >5 cm in their analysis. In addition, patients with no evidence of disease at PC-RPLND were excluded from their analysis. It is unknown what the percentage of extra-template disease would be present when restricted to patients who meet our strict selective inclusion criteria.
Distribution patterns of lymph node metastases at the time of bilateral PC-RPLND further validate modified template use in low-volume disease. Ehrlich et al. [17] reported that when stratified by clinical stage, only one out of 20 patients with clinical stage ≤IIB had a microscopic focus of teratoma outside the modified template but within the bilateral template. However, patients with large volume disease had a 20% crossover rate.
Our present results corroborate other studies investigating modified-template outcomes in specific clinical settings. In a series of 50 patients who underwent modified-template PC-RPLND for residual masses of <2 cm, there were three recurrences (6%) at a median follow-up of 80 months [18] . More recently, Heidenreich et al. [19] reported the results of 98 patients who underwent modified-template PC-RPLND for residual masses located in the primary landing zone and of <5 cm. Three patients (3.1%) subsequently developed recurrence at a median follow-up of 39 months and all recurrences were located outside the boundaries of a standard-bilateral template. These patients all underwent resection of recurrent disease and had no evidence of disease at their latest follow-up.
The potential benefits of a modified template include shorter operative times, fewer complications and reduced fluid requirements. Historically, the major morbidity associated with RPLND was anejaculation secondary to loss of seminal emission [20, 21] . Modified PC-RPLND templates avoid potential damage to the contralateral efferent sympathetic chain, which should result in preservation of antegrade ejaculation. Nearly all patients queried in our present series of modified template (43/44) had normal antegrade ejaculation, despite only 16% (16/100) undergoing nervesparing PC-RPLND. These findings mirror previously reported rates of 97% preservation of ejaculatory function with unilateral-modified template without nerve sparing in primary RPLND [22] . In the post-chemotherapy setting, the size of residual retroperitoneal mass was a factor in ejaculatory status [23] .
Sympathetic nerve preservation is possible even in patients undergoing bilateral template nerve-sparing RPLND in lowvolume disease. However, the rate of preservation is lower in the post-chemotherapy setting than in the primary setting. Heidenreich et al. [19] found a notable difference in ejaculatory status between the two patient cohorts. While nerve-sparing was achieved in 74.5% of patients who underwent a unilateral-modified template, 85% of patients ultimately had preservation of antegrade ejaculation. On the other hand, among the 55.5% of patients who underwent nerve preservation with a bilateral template, only 25% of patients maintained antegrade ejaculation. Previous studies also reported temporary anejaculation in the setting of bilateral-template dissection secondary to effects of neuropraxia [24] . However, among patients who underwent modified-unilateral-template RPLND, any period of anejaculation has been rare [14] .
The present study was limited by its observational and retrospective nature. Also of note, the present series of 100 patients was highly selective and represented <10% of the PCRPLNDs performed at our institution during the study period. Reproductive status and ejaculatory function was unable to be obtained for every patient in the cohort. Nevertheless, the success rate for ejaculatory preservation was similar to previously reported rates even in the postchemotherapy setting without sacrificing oncological efficacy.
Conclusion
In appropriately selected patients with tumour limited to the primary landing zone of the affected testis, both before and after chemotherapy, a modified-template dissection provides durable long-term oncological outcomes, while maintaining adequate ejaculatory function.
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